Herbal Medication to Treat Dry Eye in Peri/ Post-menopausal Women
Randomised Placebo Controlled Study of Herbal Medication to Treat Dry Eye in Peri/ Post-menopausal Women
2 other identifiers
interventional
150
1 country
1
Brief Summary
Dry eye disease (DED) in less severe forms are very common, and should ideally be treated outside hospitals, eg., through primary care services and exploiting holistic therapies such as traditional medicine. This will keep the care affordable and accessible despite a large burden of care. Postmenopausal women, compared to others in the population, have a higher incidence of DED. Large-scale epidemiological studies done in the United States have shown that the rate of DED in women over 50 years old is nearly double that in men over 50, at 7% and 4%, respectively. Studies have demonstrated that there is a hormonal etiology behind this group's susceptibility to DED, although the precise hormonal imbalance and mechanistic pathway for DED are still unclear. A significant number of women seen at the dry eye clinic are post-menopausal, and very symptomatic, though many do not have the corneal epitheliopathy evidenced by dye staining. Such patients are not likely to benefit from conventional prescription drugs for dry eye, such as cyclosporine and corticosteroids. Hormonal replacement therapy for menopausal women has not been universally accepted, and there may be an increased risk of carcinomas, on the other hand, topical hormonal therapy for dry eye is not widely available, and still controversial, so there is a definite unmet need for new therapeutic modalities to treat dry eye in post-menopausal women. Traditional Chinese Medicine (TCM) is a form of complementary medicine that aims to treat yin or yang deficiency syndromes, using modalities like herbs, acupuncture or moxibustion. Menopause in women, particularly in Asia, has been linked to yin-deficiency, in one study, 73% of Chinese post-menopausal women suffered from kidney yin-deficiency. A review of randomized controlled trials of TCM treatment showed that certain modalities like soy and phytoestrogens have been useful in the treatment of syndromes in menopause, such as hot flushes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for early_phase_1
Started Apr 2022
Typical duration for early_phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 22, 2022
CompletedFirst Posted
Study publicly available on registry
April 8, 2022
CompletedStudy Start
First participant enrolled
April 11, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 21, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 21, 2025
CompletedMay 15, 2025
May 1, 2025
2.9 years
March 22, 2022
May 12, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in SPEED score
To assess the improvement of dry eye symptoms by SPEED questionnaire. 0 score is the minimum (no dry eye symptom); 64 is the maximum score (most symptomatic)
3 months
Secondary Outcomes (4)
Change in SPEED score
4 months
Change in Sleep score
3 months
Change in Depression score
3 months
Change in TCM score (Liver-Kidney Yin Deficiency)
3 months
Study Arms (2)
Active herbal capsules
EXPERIMENTALWei's Qi Ju Gan Lu Formula is a herbal formulation initiated by the senior TCM collaborator, Prof Wei QP. This TCM formulation is prescribed to treat the dry eye patients with "liver-kidney yin deficiency". The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye.
Placebo capsules
PLACEBO COMPARATORPlacebo capsule which contains 0.5g maltodextrin without any herbs medicine.
Interventions
The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with "liver-kidney yin deficiency". The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye.
0.5g maltodextrin without any herbs medicine
Eligibility Criteria
You may qualify if:
- Age 40-79 years old women
- Peri and Post-menopausal women
- Chief complaint of participant should be consistent with dry eye symptoms based on SPEED Questionnaire, with a score of \> 6 (Appendix 5)
- History of presenting TCM score symptoms:
- TCM dry eye assessment score (Appendix 3) The pattern deviation can be determined if 3 or more main symptoms are present (one of which is a localized eye symptom and one of which is a system symptom), together with at least one accompanying symptom.
- Liver-Kidney yin deficiency assessment score (Appendix 4) This form is to determine the extent of Liver-Kidney Yin Deficiency (assessed at SCHMI).
- Any score\<14 will not satisfy the criterion for Liver Kidney Yin Deficiency and will not be recruited. This detailed TCM score will also be a secondary outcome measure in the analysis of pre/post herbal treatment (see below).
- Clinical signs:
- Tear break up time (TBUT) ≤10s or Schirmer I test ≤10mm/5 mins
- Normal renal and liver function at baseline, i.e., all parameters within the reference value
You may not qualify if:
- Currently or intention to use hormonal therapy (eg. cancer patients who is on tamoxifen)
- Currently pregnant or breastfeeding
- Hysterectomy procedure done previously
- Removal of cysts or polyp procedure done previously
- Requirement to wear contact lens, and having worn such lenses in week preceding eligibility
- Glaucoma, significant cataract, age related macular degeneration or other ophthalmic disease, eg. Extraocular muscle palsies, facial paralysis, ectropion, entropion, trichiasis
- Requirement of any eyedrops other than artificial tears.
- Previous eye surgeries including LASIK (within 6 months) or punctal plugs in-situ
- Autoimmune systemic diseases: Steven-Johnson syndrome, Sjogren's syndrome, Rheumatoid Arthritis, Lupus
- Systemic disease requiring regular medication (except hypertension and lipidemia)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Singapore National Eye Centre
Singapore, Singapore
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Louis Tong, PhD
Singapore National Eye Centre
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 22, 2022
First Posted
April 8, 2022
Study Start
April 11, 2022
Primary Completion
February 21, 2025
Study Completion
February 21, 2025
Last Updated
May 15, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share